Matsumura Tomoaki, Arai Makoto, Maruoka Daisuke, Okimoto Kenichiro, Minemura Shoko, Ishigami Hideaki, Saito Keiko, Nakagawa Tomoo, Katsuno Tatsuro, Yokosuka Osamu
Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba-City 260-8670, Japan.
BMC Gastroenterol. 2014 Oct 3;14:172. doi: 10.1186/1471-230X-14-172.
Endoscopic submucosal dissection (ESD) has become widely accepted as a standard treatment for gastric epithelial neoplasms. Antithrombotic agents are widely used to prevent thromboembolic disease. However, the feasibility of endoscopic procedures for patients using such agents has been rarely investigated. The aim of this study was to identify risk factors for post-operative bleeding after gastric ESD and to evaluate the relationship between the use of antithrombotic agents and post-operative bleeding.
From June 2005 to March 2014, 413 patients with 425 gastric neoplasms were treated by ESD. The demographic and clinical parameters associated with post-operative bleeding were investigated. 83 patients receiving antithrombotic agents were separately assessed using various methods of administration during the ESD procedure. Post-operative bleeding that occurred within 5 days of ESD was defined as early post-operative bleeding, whereas subsequent bleeding was defined as delayed bleeding.
The overall post-operative bleeding rate was 4.7%. In patients with continued low-dose aspirin (LDA), heparin replacement (HR), or continued LDA along with HR, post-operative bleeding rates were 9.5%, 23.8%, and 25.0%, respectively. On multivariate analysis, a specimen size of ≥40 mm was a risk factor for early post-operative bleeding [odds ratio (OR) 6.08, 95% CI: 1.74-21.27], and HR and chronic kidney disease (CKD) requiring hemodialysis were risk factors for delayed bleeding (OR 12.23, 95% CI: 2.63-56.77 and OR 28.35, 95% CI: 4.67-172.11, respectively). Continued LDA was not a risk factor for post-operative bleeding.
Large specimen size is a risk factor for early post-operative bleeding, and HR and CKD requiring hemodialysis are risk factors for delayed bleeding. Patients with risk factors should be carefully watched, allowing for the timing of post-operative bleeding after ESD.
内镜黏膜下剥离术(ESD)已被广泛认可为胃上皮性肿瘤的标准治疗方法。抗血栓药物被广泛用于预防血栓栓塞性疾病。然而,针对使用此类药物的患者进行内镜手术的可行性鲜有研究。本研究的目的是确定胃ESD术后出血的危险因素,并评估抗血栓药物的使用与术后出血之间的关系。
2005年6月至2014年3月,413例患有425个胃肿瘤的患者接受了ESD治疗。研究了与术后出血相关的人口统计学和临床参数。83例接受抗血栓药物治疗的患者在ESD手术过程中使用了各种给药方法进行单独评估。ESD术后5天内发生的出血定义为术后早期出血,而随后发生的出血定义为延迟出血。
总体术后出血率为4.7%。在持续使用小剂量阿司匹林(LDA)、肝素替代(HR)或持续使用LDA并联合HR的患者中,术后出血率分别为9.5%、23.8%和25.0%。多因素分析显示,标本大小≥40 mm是术后早期出血的危险因素[比值比(OR)6.08,95%置信区间(CI):1.74 - 21.27],HR和需要血液透析的慢性肾脏病(CKD)是延迟出血的危险因素(OR分别为12.23,95% CI:2.63 - 56.77和OR 28.35,95% CI:4.67 - 172.11)。持续使用LDA不是术后出血的危险因素。
大标本大小是术后早期出血的危险因素,HR和需要血液透析的CKD是延迟出血的危险因素。有危险因素的患者应密切观察,以便确定ESD术后出血的时间。